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UM RESEARCHER HONES A NEW WEAPON 
TO FIGHT MALARIA IN AMAZON JUNGLE
By Dan Struckman 
Office of University Relations 
University of Montana
MISSOULA--
You might walk past him every day and never suspect that as his
fellow graduate students call him, is not the garden variety microbiology student. 
For one thing, the slender--a bit gaunt--35-year-old man has lived most of his 
life in the Amazon jungle.
For another, he is a licensed physician in Brazil and teaches infectious 
disease courses at the Hospital for Tropical Diseases, University of the Amazon, 
Manaus, Brazil. Manaus, a city of about a million people, lies about 1,500 miles 
up the Amazon River.
For a third thing, he is head of malaria research at the National Research 
Institute of the Amazon, the only center for infectious disease research in the 
region.
And malaria, contrary to widespread belief, is not a disease of the past. 
Despite the best efforts of medicine, despite progress made by the World Health 
Organization (WHO) and the latest technology, malaria still kills a person each 
second. That’s more than two million a year. That's more than any othei trans­
missible disease.
Dr. Jose J. ("J.J.") Ferraroni, a shy, soft-spoken man, had wanted to find 
out about a promising new drug used to prevent and treat malaria, but his work 
load in Brazil required 16 hours daily of him. He had previously met Dr.
(over)
Clarence A. Speer, associate professor of microbiology at the University of 
Montana, so he asked Speer if he could do malaria research in Missoula.
Dr. Ferraroni found he could, and received paid leave from Manaus to come 
to UM.
He and his wife and daughter moved from the heat of 100-degree tropical 
Amazon to the relative coolness of Missoula in July 1978. His wife, Maria Jose, 
works as a pediatrician in Manaus. While in Missoula, she gave birth to twin 
girls.
Once enrolled as a UM graduate student, Dr. Jose Ferraroni designed exper­
iments to test the new drug. He distinguished himself academically, winning the 
$1,000 Bertha Morton Scholarship this year.
The drug he was studying, Fansidar, is really a combination of two drugs 
previously used to treat malaria, he said. The organism that causes malaria, a 
protozoan transmitted by mosquito bites, often develops resistance to drugs used 
to kill it. Once resistance to a drug develops, he said, the medicine becomes 
worthless.
Although the manufacturer, Hoffman-LaRoche, had tested separately the two 
components in Fansidar, the combination had not been researched adequately,
Dr. Ferraroni said.
Fansidar, available only outside the United States, is not subject to the 
same rigorous testing required by the Food and Drug Administration for drugs 
sold within the United States.
Using white mice and a special malarial protozoan to infect them, Dr. 
Ferraroni found out how much drug to use and how often to use it to prevent or 
treat malaria in mice.
Additionally, Dr. Ferraroni examined the nature of immunity to malaria.




infections, he said. He was able to immunize mice by repeatedly inoculating 
the mice with malaria and curing them with Fansidar, he explained.
Last week, when he successfully concluded his research and thesis for his 
Ph.D. from UM, Dr. Ferraroni said he was pleased with the quality of his results, 
and that he has new insight into treating malaria in humans.
"I am really grateful tc the Brazilian government and to Dr. Speer and the 
faculty of the UM microbiology department,” he said.
But Dr. Ferraroni still believes that the incidence of malaria will con­
tinue to accelerate, despite his new drug. He speaks quietly and with a little 
sadness when he describes the hopelessness and enormity of the malaria problem.
He predicts that in five years resistant protozoa will render Fansidar as worth­
less as previously-used drugs.
When a person is infected by the malarial organism by being bitten by an 
infected mosquito, the protozoa invade the victim's liver;then the red blood cells
are invaded and destroyed, leading to problems in the brain, kidneys and other 
vital organs.
The disease starts out with fever and shivering and can progress to coma and 
death. About one in 10 persons infected will die, especially if he has the 
deadliest form of malaria, that caused by plasmodium falciparum. Dr. Ferraroni
said the new drug may be able to save many lives, but the malaria problem world­
wide will continue to escalate.
A large part of the problem, he said, is the simple lack of economic incen­
tive to do malaria research. In the United States and other highly developed 
nations, malaria is not much of a problem. Instead, research in the United States 
is focused on cancer and heart disease, he said.
'People in the Amazon jungle don't live long enough to develop cancer or 
heart disease," he said.
He admits that the rich in his home city of Manaus are also prone to cancer
(over)
MALARIA--add three
and heart disease, and for that reason his own medical school does research in 
those areas.
Malaria, however, is mostly a disease of the rural poor of tropical areas, 
such as Central Africa, Southeast Asia, India, Southern Mexico, Central America 
and Northern South America.
"We don't have the means to do much research in malaria," he said. Instead, 
Dr. Ferraroni and his colleagues depend largely on the research of the more 
advanced countries. The trouble is, such research is not often done, he said.
Lack of research is not the only reason malaria is a growing threat, he 
said. Logistics is perhaps the greatest stumbling block of all.
To illustrate the problem, Dr. Ferraroni says that when people suggest that 
researchers develop a vaccine to immunize people against malaria, he tells them 
that even if such a vaccine were to miraculously appear before them, the malaria 
problem would continue to grow for at least 50 more years.
For a vaccine to work, people need to be reached to be educated first, he
said.
"The tribal people living in the jungle have never seen hypodermic needles 
and would not understand why they should be injected, he said.
"Our city is 1,500 miles from the nearest city, and the only transportation 
is by air or by river boat."
Transportation difficulties alone would prevent the successful attack on 
malaria by immunization, he said.
A third problem, one that Dr. Ferraroni hesitates to voice, is that the
government officials in the equatorial nations do not want to frighten away
tourists. As a result, the officials downplay the seriousness of the malaria
problem. And, he adds, malaria really isn't such a problem in cities, where
good medical facilities exist, but the lack of public awareness about malaria has 
been detrimental to the effort of the research.





CUTLINE FOR PHOTO W/"UM RESEARCHER HONES..."
FROM MANAUS, BRAZIL-Dr. Jose J. Ferraroni came to Montana to study a new anti- 
malaria drug at the University of Montana. Armed with new knowledge, Dr. Ferraroni 
hopes to reduce the number of deaths from malaria in the Amazon region when he returns 
to Brazil at the end of November. (UM photo by Leslie Vining)
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